Switching the fiber knob of oncolytic adenoviruses to avoid neutralizing antibodies in human cancer patients

Oncolytic Adenovirus Coding for Granulocyte Macrophage Colony-Stimulating Factor Induces Antitumoral Immunity in Cancer Patients

(2010) Vincenzo Cerullo et al.   CANCER RESEARCH

Oncolytic Adenovirus ICOVIR-7 in Patients with Advanced and Refractory Solid Tumors

(2010) P. Nokisalmi et al.   CLINICAL CANCER RESEARCH

Prolonged systemic circulation of chimeric oncolytic adenovirus Ad5/3-Cox2L-D24 in patients with metastatic and refractory solid tumors

(2010) S Pesonen et al.   GENE THERAPY

Treatment of Cancer Patients With a Serotype 5/3 Chimeric Oncolytic Adenovirus Expressing GMCSF

(2010) Anniina Koski et al.   MOLECULAR THERAPY

Desmoglein 2 is a receptor for adenovirus serotypes 3, 7, 11 and 14

(2010) Hongjie Wang et al.   NATURE MEDICINE

A modified E2F-1 promoter improves the efficacy to toxicity ratio of oncolytic adenoviruses

(2009) J J Rojas et al.   GENE THERAPY

Ad5/3-9HIF-Δ24-VEGFR-1-Ig, an infectivity enhanced, dual-targeted and antiangiogenic oncolytic adenovirus for kidney cancer treatment

(2009) K Guse et al.   GENE THERAPY

In situ adenovirus vaccination engages T effector cells against cancer

(2009) Sebastian Tuve et al.   VACCINE

Changing the adenovirus fiber for retaining gene delivery efficacy in the presence of neutralizing antibodies

(2008) M Särkioja et al.   GENE THERAPY

A smart move against cancer for vaccinia virus

(2008) Ramon Alemany   LANCET ONCOLOGY